Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib and FSRS for Recurrent High Grade Gliomas
NCT02186509Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jan 2015
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alisertib in glioma, sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Maximum Tolerated Dose. Started Jan 2015; status: completed.
02
Drugs
alisertib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT02186509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02186509.